2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 753

Identification of IL12RB1 As a Novel Systemic Sclerosis Susceptibility Locus
Abstract Number: 608

Identification of Novel Autoantibodies in Patients with Ankylosing Spondylitis Using Human Protein Microarray
Abstract Number: 1730

Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Abstract Number: 982

Identification of Potential SERUM Autoantibody Biomarkers in Rheumatic Diseases Using a New Generation of Protein Arrays
Abstract Number: 2747

Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis
Abstract Number: 1043

Identification of Putative Biomarkers and Molecular Mechanisms Associated with Adverse Tissue Reactions to Metal-on-Metal and Modular Neck Hip Implants
Abstract Number: 76

Identification of Synovial Genes and Pathways Associated with Disease Progression in a Cohort of Early Symptomatic Osteoarthritis Patients Using a Transcriptomic Approach
Abstract Number: 1723

Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies
Abstract Number: 97

Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data
Abstract Number: 2787

Identification of Urinary Biomarkers for Lupus Nephritis
Abstract Number: 2982

Identification of Whole Blood Gene Expression Signature in Primary Sjögren’s Syndrome Associated Lymphoma
Abstract Number: 1055

Identifying Flare in Rheumatoid Arthritis (RA): Performance of the Flare-Assessment in RA (FLARE) Questionnaire in a US Population
Abstract Number: 2841

Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide
Abstract Number: 1668

Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis
Abstract Number: 1604

IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].